ARTICLE | Clinical News
DAC:GLP-1: CJC started a placebo-controlled Dutch Phase I dose-ranging study of DAC:GLP-1 in up to 110 subjects. In the first part of the study, up to 58 volunt
July 15, 2002 7:00 AM UTC
ConjuChem Inc. (TSE:CJC), Montreal, Quebec Product: DAC:GLP-1 (CJC-1131) Business: Metabolic Therapeutic category: Metabolism Target: GLP-I receptor Description: Analog of glucagon-like peptide-1 (GL...